Back to Search
Start Over
Living donor liver transplantation for end-stage hepatitis C.
- Source :
-
Transplantation proceedings [Transplant Proc] 2004 Jun; Vol. 36 (5), pp. 1481-2. - Publication Year :
- 2004
-
Abstract
- Living donor liver transplantation is important for patients with end-stage viral hepatitis because of the shortage of organs from deceased donors. However, preliminary results indicate that living liver donation might be disadvantageous for hepatitis C virus-positive patients. Twenty-seven patients who underwent living donor liver transplantation for hepatitis C virus cirrhosis preemptively received antiviral therapy using interferon-alpha2b and ribavirin, which was started an average of 32 days after the operation and continued for at least 6 months thereafter. The serum hepatitis C virus RNA became negative in the 8 of 16 patients with more than 1 year follow-up. The cumulative 3-year patient survival was 85%, which was comparable to that of hepatitis C virus negative patients (n = 93; 90%). Preemptive antiviral therapy after transplantation may be necessary for satisfactory results after living donor liver transplantation.<br /> (Copyright 2004 Elsevier Inc.)
Details
- Language :
- English
- ISSN :
- 0041-1345
- Volume :
- 36
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Transplantation proceedings
- Publication Type :
- Academic Journal
- Accession number :
- 15251363
- Full Text :
- https://doi.org/10.1016/j.transproceed.2004.04.076